Abstracts tagged "arthritis and psoriatic arthritis"

Abstract Number: 1779 • 2019 ACR/ARP Annual Meeting
CLEC5A/MDL-1 Is Critical for Inflammatory Arthritis and Skin Inflammation
Cuong Nguyen¹, Dai Hui ¹, Ran Gu ¹, Trevor Chan ², Alina Marleev ³, Emanual Maverakis ³, Vijay Kuchroo ⁴, Shie-Liang Hsieh ⁵, Ilias Tagkopoulos ², Christopher Ritchlin ⁶ and Iannis Adamopoulos ¹, ¹Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis, Sacramento, CA, ²University of California, Davis, Department of Computer Science, California, USA, Davis, CA, ³Department of Dermatology, School of Medicine, UCD, Sacramento, California, USA., Sacramento, CA, ⁴Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, MA, USA, Boston, MA, ⁵Genomics Research Center, Academia Sinica, 128 Academia Road, Section 2, Nankang, Taipei, Taiwan, Taipei, Taiwan (Republic of China), ⁶Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY
Background/Purpose: Interleukin-23 (IL-23) and its cognate receptor interleukin-23R (IL-23R):IL-12Rβ1 plays a critical role in the pathogenesis of autoimmune diseases including psoriasis and psoriatic arthritis. Although…
Abstract Number: 2557 • 2018 ACR/ARHP Annual Meeting
Efficacy of Ustekinumab on Spondylitis-Associated Endpoints in TNF-Naïve Active Psoriatic Arthritis Patients with Physician-Reported Spondylitis
Philip Helliwell¹, Dafna D Gladman², Soumya D Chakravarty³, Shelly Kafka⁴, Chetan S Karyekar⁴, Yin You⁵, Arthur Kavanaugh⁶ and Lianne S. Gensler⁷, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, UK, Leeds, United Kingdom, ²Department of Medicine, Toronto Psoriatic Arthritis Research Program, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Janssen Scientific Affairs, LLC/Drexel University School of Medicine, Horsham/Phila, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶University of California, San Diego, School of Medicine, La Jolla, CA, ⁷University of California San Francisco, San Francisco, CA
Background/Purpose: In PSUMMIT 1&2, Phase 3 trials of ustekinumab (UST) in adults w/ active psoriatic arthritis (PsA), 30.1% & 22.4% of patients (pts) had peripheral…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].